Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Talazoparib and Avelumab in Genomically Defined Metastatic Renal Cell Carcinoma

NCT04068831 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT04068831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04068831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Talazoparib and Avelumab in Genomically Defined Metastatic Renal Cell Carcinoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
August 22, 2019
Completion date
December 6, 2023
Enrollment
18 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

fumarate hydratase deficient renal cell carcinoma, metastatic renal cell carcinoma, succinate dehydrogenase deficient renal cell carcinoma